Testicular Germ Cell Tumors (TGCTs) are the most common type of cancer affecting younger men between the ages of 20 and 40 years old. TGCTs typically respond well to current treatments, yet about 5% of cases are resistant. Furthermore, current treatments can have many adverse side affects that extend later in life warranting the need for improved, more targeted therapies. However, the genetic and molecular causes of TGCTs are largely unknown. To develop improved treatments for this disease requires a better understanding of the molecular underpinnings of TGCT formation.
The aims of the project are to uncover mutations that drive TGCT tumorigenesis and/or increase susceptibility, and identify putative causative variants in human TGCTs through two main approaches: 1) develop an animal model with a high incidence of TGCTs, and 2) genome sequencing of tumor samples derived from patients. TGCTs consist of several subtypes, only one of which has an available mammalian model. Furthermore, TGCT cell lines are notoriously difficult to derive and are therefore largely unavailable. The zebrafish is an excellent animal model for many human diseases, including cancer. Strikingly, two zebrafish mutant lines have been identified that give rise to seminoma-type TGCT, which is the most common TGCT. Studies of these existing mutants identified mutated or misregulated genes in human TGCTs. We identified a novel zebrafish mutant line with a high incidence of TGCTs, named zgt (zebrafish germ cell tumor). This mutant is distinct from known zebrafish TGCT mutants and thus provides novel inroads to discovering molecular mechanisms underlying TGCT formation. To test for drivers of TGCTs in humans, this pilot proposes a genomic sequencing approach of patient samples with the goal of discovering mutations that arise during TGCT formation and thus may drive tumorigenesis. To facilitate identification of rare alleles, the project will use the knowledge gained from studies of our zebrafish model to guide targeted searches for mutations in human patient samples. This approach will facilitate the identification of mutations that may drive tumorigenesis, even with a limited number of primary tumor samples. Through this work, this pilot project will establish a new animal model for TGCT studies that will be used to uncover genetic and mechanistic causes of tumor formation. The project will translate the knowledge gained from the animal model through comparisons with genomic analysis attained from tumors derived from human patients, which will facilitate the identification of potential areas for therapeutic intervention. This project directly relates to the goals of the U54 Partnership as it supports collaborative research between oncologists and pathologists at DF/HCC and a basic science research group at UMass Boston. This collaboration is essential in establishing the project's translational model and building the cancer research program at UMass Boston. Furthermore, this project will provide opportunities for underrepresented minority (URM) students to engage in cancer research, and support career development of early stage investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA156732-07
Application #
9355113
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
7
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Balboni, Michael J; Sullivan, Adam; Smith, Patrick T et al. (2018) The Views of Clergy Regarding Ethical Controversies in Care at the End of Life. J Pain Symptom Manage 55:65-74.e9
Koss, Sarah E; Weissman, Ross; Chow, Vinca et al. (2018) Training Community Clergy in Serious Illness: Balancing Faith and Medicine. J Relig Health :
Ramanadhan, Shoba; Minsky, Sara; Martinez-Dominguez, Vilma et al. (2017) Building practitioner networks to support dissemination and implementation of evidence-based programs in community settings. Transl Behav Med 7:532-541
Balboni, Michael J; Sullivan, Adam; Enzinger, Andrea C et al. (2017) U.S. Clergy Religious Values and Relationships to End-of-Life Discussions and Care. J Pain Symptom Manage 53:999-1009
Leyva, Bryan; Allen, Jennifer D; Ospino, Hosffman et al. (2017) Enhancing capacity among faith-based organizations to implement evidence-based cancer control programs: a community-engaged approach. Transl Behav Med 7:517-528
Park, Elyse R; Mutchler, Jan E; Perez, Giselle et al. (2017) Coping and resiliency enhancement program (CARE): a pilot study for interpreters in cancer care. Psychooncology 26:1181-1190
Allen, Jennifer D; Torres, Maria Idalí; Tom, Laura S et al. (2016) Dissemination of evidence-based cancer control interventions among Catholic faith-based organizations: results from the CRUZA randomized trial. Implement Sci 11:74
LeBaron, Virginia T; Smith, Patrick T; Quiñones, Rebecca et al. (2016) How Community Clergy Provide Spiritual Care: Toward a Conceptual Framework for Clergy End-of-Life Education. J Pain Symptom Manage 51:673-81
Trevino, Kelly M; Zhang, Baohui; Shen, Megan J et al. (2016) Accuracy of advanced cancer patients' life expectancy estimates: The role of race and source of life expectancy information. Cancer 122:1905-12
Abel, Gregory A; Albelda, Randy; Khera, Nandita et al. (2016) Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1504-1510

Showing the most recent 10 out of 73 publications